Labs fear future funding cuts with Trump administration actions in limbo
A series of actions by President Donald Trump's administration have provoked profound anxiety among academic labs that undergird biomedical research. These policies — including slashing overhead...
View ArticleUpdated: Moderna earnings: Losses narrow as biotech cuts costs
Moderna is working on restoring investors' faith that its Covid-19 vaccine was not a one-hit-wonder. It also has to show it can get its costs under control. On Friday, the company announced...
View ArticleBristol Myers’ Opdualag stumbles in late-stage resected melanoma trial
Bristol Myers Squibb’s LAG-3/PD-1 targeting immunotherapy Opdualag failed to boost survival in patients with advanced skin cancer in a Phase 3 study, marking the latest flop for an approach that has a...
View ArticleDavid Schenkein resigns from Agios’ board; Moderna hires Roivant exec as...
David Schenkein will step down from Agios Pharmaceuticals’ board of directors at the end of the month "to devote more time to his other commitments," according to its earnings report Thursday. He will...
View ArticleHow Bain’s $3.3B deal for a centuries-old Japanese pharma came to fruition
About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting the leadership of Tanabe Pharma and its parent Mitsubishi Chemical ...
View ArticleBioNTech vets raise about $90M in Series A for bispecific immunology research
A new immunology biotech closed its Series A, and it’s backed by investors intricately familiar with the industry. Bambusa Therapeutics said Friday that it raised “approximately” $90 million in the...
View ArticleOtsuka makes pipeline changes; Oculis reveals $100M offering
Plus, news about Aardvark’s IPO: Otsuka cuts cancer programs: The drugmaker is stopping development of OPB-111077, an oral STAT inhibitor, for hematological cancers in the US. It also terminated...
View Article#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data for Nectin-4 ADC
Corbus Pharmaceuticals reported encouraging early-stage results for its Nectin-4 targeting ADC in various types of cancer, but a lack of response in certain patients caused shares to slide. The...
View ArticleWest Pharma loses two glucose device clients but is buoyed by its GLP-1...
West Pharmaceuticals Services’ stock {$WST} tanked by as much as 38% late Thursday after the packaging and delivery system provider said it was ending major contracts with two unnamed glucose...
View ArticleKojin Therapeutics shuts down, citing lack of investor interest and complex...
Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan Healthcare Conference in a bind. It needed bridge financing to stay afloat...
View ArticleDrugmakers plan Trump meeting next week amid health shakeups
Major drugmakers are planning to meet with President Donald Trump next week at the White House as part of the industry’s effort to work with the new administration. The details of the meeting are still...
View ArticleARPA-H chief is out as Trump administration cuts health agencies
Renee Wegrzyn has been let go as the head of a federal agency that pursues ambitious ideas to accelerate biomedical innovation, part of a broad series of ongoing changes being made by the new Trump ...
View ArticleJ&J to face pivotal hearing over its $8B talc settlement plan
Johnson & Johnson is set to push for confirmation of a bankruptcy plan next week that would settle a vast majority of cases alleging the company’s talc products caused cancer. The controversial...
View ArticleNIH, CDC cuts expected as Trump shakeup hits healthcare
The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide cuts planned across several major health organizations and hints of more to...
View Article#ASCOGU: Lilly’s early bladder cancer data hint at safety edge over J&J’s...
Eli Lilly has shared first-in-human results for its selective FGFR3 inhibitor in a subset of bladder cancer patients, marking the start of a program that could eventually challenge Johnson &...
View ArticleGSK follows Pfizer in meningococcal vaccine race with new FDA nod
GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer. Penmenvy was approved Friday for children and young adults ages 10 to 25. Chief...
View ArticleUpdates from Washington; A trio of Big Pharma deals; What do recent share...
Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week! Robert F. Kennedy Jr. is officially leading HHS as of Thursday ...
View ArticlePain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod
Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug approval last month, is targeting up to $150 million in a new funding round,...
View ArticleFDA approves Ono’s rare joint tumor drug, setting up battle with Daiichi
The FDA approval of Romvimza in a rare cancer means Ono Pharmaceutical has a fight on its hands. The company must work to displace Daiichi Sankyo’s Turalio, and fortunately, Romvimza appears to have...
View ArticleExclusive: AI biotech Atomwise hires new CEO, raises $45M Series C
Atomwise spent most of its first 12 years talking up the potential of AI in making molecules. Now, the biotech startup is turning to an industry veteran with over 35 years of biotech experience to ...
View Article